[No title available]
- PMID: 40453171
- PMCID: PMC12125549
- DOI: 10.1016/j.jccase.2025.02.009
[No title available]
Conflict of interest statement
Toru Kubo and Hiroaki Kitaoka have received consulting fees or honoraria and remuneration for lectures from Pfizer Japan Inc. Hiroaki Kitaoka and Toru Kubo are members of the editorial team of Journal of Cardiology Cases. The remaining authors have no conflicts of interest to declare.
References
-
- Donnellan E., Wazni O., Kanj M., Elshazly M.B., Hussein A., Baranowski B., Hanna M., Patel D., Trulock K., Martyn M., Menon V., Saliba W., Jaber W.A. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace. 2020;22:259–264. - PubMed
-
- Litwin S.E., Komtebedde J., Borlaug B.A., Kaye D.M., Hasenfuβ G., Kawash R., Hoendermis E., Hummel S.L., Cikes M., Gustafsson F., Chung E.S., Mohan R.C., Sverdlov A.L., Swarup V., Winkler S., et al. Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials. Am Heart J. 2024;278:106–116. - PubMed
-
- Nakatani Y., Sridi-Cheniti S., Cheniti G., Ramirez F.D., Goujeau C., André C., Nakashima T., Eggert C., Schneider C., Viswanathan R., Krisai P., Takagi T., Kamakura T., Vlachos K., Derval N., et al. Pulsed field ablation prevents chronic atrial fibrotic changes and restrictive mechanics after catheter ablation for atrial fibrillation. Europace. 2021;23:1767–1776. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources